Related Experiment Videos
Models for assessing scar tissue inhibitors
Abstract:
The main purpose of animal models for proliferative vitreoretinopathy (PVR) is to develop pharmacologic therapies for this common cause of blindness. A very large number of pharmacologic agents appear to have potential use in this application by preventing cell proliferation and/or contraction. In practice, however, it has been found that prohibitively extensive numbers of animals and laboratory services are required to establish drug efficacy, safety, and dosage regimes. To lessen this work load and to accelerate drug screening programs, the authors have developed an in vitro model for PVR based on chorioretinal fibroblast growth in three-dimensional collagen lattices. This model yields precise data on the effect of drugs on cell proliferation and contractility. Trifluoperazine, colchicine, 5-fluorouracil, dexamethasone, and penicillamine were screened in this model. The first three agents were found to be inhibitory; on the basis of the pharmacokinetic data, obtained dosage regimes for animal testing were developed. The results obtained are discussed in terms of the in vitro model and the biochemical action of these drugs on the cellular events in PVR. In vitro screening of drugs prior to animal testing offers a significant advance in the quest for a pharmacologic prevention of blindness due to PVR.
Insights
An innovative in vitro model for proliferative vitreoretinopathy (PVR) accelerates drug screening. This model precisely measures drug effects on cell growth and contraction, reducing the need for extensive animal testing in developing therapies for blindness.
Area of Science:
- Ophthalmology
- Cell Biology
- Pharmacology
Background:
- Proliferative vitreoretinopathy (PVR) is a common cause of blindness.
- Developing effective pharmacologic therapies for PVR is crucial.
- Current animal models for PVR drug development are resource-intensive.
Purpose of the Study:
- To develop an in vitro model for PVR to accelerate drug screening.
- To precisely measure the effects of pharmacologic agents on cell proliferation and contractility.
- To reduce the workload and cost associated with traditional animal testing.
Main Methods:
- Developed an in vitro model using chorioretinal fibroblast growth in 3D collagen lattices.
- Screened five pharmacologic agents: trifluoperazine, colchicine, 5-fluorouracil, dexamethasone, and penicillamine.
- Collected precise data on drug effects on cell proliferation and contractility.
Main Results:
- The in vitro model provided precise data on drug efficacy.
- Trifluoperazine, colchicine, and 5-fluorouracil demonstrated inhibitory effects on cell proliferation/contraction.
- Pharmacokinetic data allowed for the development of dosage regimes for subsequent animal testing.
Conclusions:
- In vitro screening of drugs for PVR is a significant advancement.
- This model reduces the need for extensive animal testing, accelerating therapeutic development.
- Offers a more efficient pathway for discovering pharmacologic preventions for PVR-induced blindness.